现代妇产科进展2017，Vol.26Issue(8)：574-577,4.DOI:10.13283/j.cnki.xdfckjz.2017.08.003
同步放化疗治疗Ib2和IIa2期宫颈癌疗效及预后相关因素分析
Analysis of efficacy and prognostic factors of concurrent chemoradiotherapy in patients with stage Ib2 and IIa2 cervical cancer
摘要
Abstract
Objective:To investigate the efficacy and side effects of concurrent chemoradiotherapy in the treatment of stage Ib2 and IIa2 cervical cancer,and to analyze the prognostic factors.Methods:The clinicopathologic data of patients with stage Ib2 and IIa2 cervical cancer who received concurrent chemoradiotherapy from Jan.2000 to Dec.2010 in our hospital,were analyzed retrospectively.The overall response rate and disease control rates were used to evaluate the short-term outcomes.The 3-year,and 5-year disease-free survival (DFS) and overall survival (OS) were used to evaluate the long-term efficacy.The toxicity reactions were recorded,and the relevant prognostic factors were discussed.Results:The overall response rate (CR+PR) and disease control rate (CR+PR+SD) of concurrent chemoradiotherapy in patients with stage Ib2 and IIa2 cervical cancer were 91.78%,97.26 %,respectively.The 3-year DFS was 84.93%,the 3-year OS was 86.30%.The 5-year DFS was 79.45% and the 5-year OS was 82.19%.All side effects can be tolerated and can be alleviated by symptomatic treatment.The univariate analysis showed that tumor pathological type,differentiated degree,size of primary tumor,lymph node metastasis and squamous cell carcinoma antigen (SCC-Ag) levels before and after treatment were closely related to the survival (P<0.05).Further multivariate analysis showed that tumor pathological type,size of primary tumor,lymph node metastasis and SCC-Ag levels after treatment 1 month were the independent prognostic factors for long-term outcome.Conclusions:The short term and long term efficacy of concurrent chemoradiotherapy in the treatment of stage Ib2 and IIa2 cervical cancer is clear and definite.The toxic side effects can be tolerated.So it is an alternative method.In this part of the patients,adenocarcinoma,tumor diameter﹥5cm,with lymph node metastasis and SCC-Ag levels ≥1.5ng/mL after treatment 1 month with poor prognosis,further study should be strengthened in these patients.关键词
同步放化疗/局部晚期宫颈癌/疗效/预后Key words
Concurrent chemoradiotherapy/Locally advanced cervical cancer/Efficacy/Prognostic分类
医药卫生引用本文复制引用
刘瑶,孔为民,宋丹,刘婷婷..同步放化疗治疗Ib2和IIa2期宫颈癌疗效及预后相关因素分析[J].现代妇产科进展,2017,26(8):574-577,4.基金项目
北京市科委生物医药与生命科学创新培育研究项目资助(No:Z151100003915149) （No:Z151100003915149）
